Scientists test new drug duo to attack tough cancers
NCT ID NCT04585958
Summary
This early-stage study is testing a new combination of two drugs, DS-8201a and olaparib, for people with advanced cancers that have a protein called HER2. The main goal is to find the safest and most effective dose. Researchers will also check if the treatment helps shrink or control the cancer in patients who have run out of other options.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MALIGNANT SOLID NEOPLASM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana-Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
Contact
Contact Phone: •••-•••-••••
-
Mayo Clinic Hospital in Arizona
ACTIVE_NOT_RECRUITINGPhoenix, Arizona, 85054, United States
-
Mayo Clinic in Florida
RECRUITINGJacksonville, Florida, 32224-9980, United States
Contact
Contact Phone: •••-•••-••••
-
Mayo Clinic in Rochester
RECRUITINGRochester, Minnesota, 55905, United States
Contact
Contact Phone: •••-•••-••••
-
University of Pittsburgh Cancer Institute (UPCI)
RECRUITINGPittsburgh, Pennsylvania, 15232, United States
Contact
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.